For US Healthcare Professionals
Onboarding steps made convenient with PONVORY®1-4
Unlike any other S1P modulator, PONVORY® hasthe unique combination of1-4:
No known food
No known drug
Before initiation of treatment with PONVORY®, assess the following based on individual patient needs: complete blood count, cardiac evaluation, liver function tests, ophthalmic evaluation, current or prior medications with immune system effects, and vaccinations.1
S1P = sphingosine-1-phosphate; SSRI = selective serotonin reuptake inhibitor.
See the pretests and assessments required before initiating PONVORY® >
For select patients, first dose monitoring is recommended1
Because initiation of PONVORY® treatment results in a decrease in heart rate (HR), with1:first dose, 4-hour monitoring is recommended for patients
- Sinus bradycardia (HR <55 beats per minute [bpm])
- First- or second-degree atrioventricular (AV) block (Mobitz type I)
- History of myocardial infarction or heart failure occurring >6 months prior to treatment initiation and in stable condition
For select patients who require first dose monitoring1:
ADMINISTER the first dose of PONVORY® in a setting where resources to appropriately manage symptomatic bradycardia are available
MONITOR patients for 4 hours after the first dose for signs and symptoms of bradycardia with a minimum of hourly pulse and blood pressure measurements
OBTAIN an ECG in these patients prior to dosing and at the end of the 4-hour observation period
For more detailed information about first dose monitoring,
please see Section 2.3 in the PONVORY® full Prescribing Information.
Before initiation of treatment with PONVORY®, assess the following1:
AV = atrioventricular; CBC = complete blood count; ECG = electrocardiogram; MS = multiple sclerosis; VZV = varicella-zoster virus.